VEA
AMLX icon

Virtus ETF Advisers’s Amylyx Pharmaceuticals AMLX Stock Holding History

Virtus ETF Advisers’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,849
Closed -$73.4K – 453
2024
Q1 		$73.4K Buy
25,849
+3,719
+17% +$48.6K 0.04% 402
2023
Q4 		$326K Buy
22,130
+9,907
+81% +$152K 0.21% 210
2023
Q3 		$224K Sell
12,223
-1,583
-11% -$33.5K 0.14% 234
2023
Q2 		$298K Buy
13,806
+5,346
+63% +$144K 0.18% 207
2023
Q1 		$248K Buy
8,460
+153
+2% +$5.32K 0.14% 288
2022
Q4 		$307K Buy
+8,307
New +$295K 0.16% 255

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtus ETF Advisers's AMLX Position: Q2 2024 in Review

Virtus ETF Advisers sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2024, closing a stake of 25,849 shares — an estimated $73.4K sold.

Virtus ETF Advisers first reported a position in AMLX in Q4 2022 and held it in 6 quarters. The position peaked at $326K in Q4 2023. 119 funds tracked by Wall St. Rank hold AMLX as of Q2 2024.

  • Virtus ETF Advisers reported no remaining Amylyx Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Virtus ETF Advisers sold 25,849 Amylyx Pharmaceuticals shares in Q2 2024, an estimated $73.4K.
  • Virtus ETF Advisers first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • Virtus ETF Advisers's Amylyx Pharmaceuticals position peaked at $326K in Q4 2023.
  • 119 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2024.

Based on Virtus ETF Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.